Essentiality of FASII pathway for Staphylococcus aureus

Nature

Volumn 463, Issue 7279, 2010, Pages

  Balemans, Wendy ^a   Lounis, Nacer ^a   Gilissen, Ron ^b   Guillemont, Jerome ^c   Simmen, Kenny ^a   Andries, Koen ^a   Koul, Anil ^a  

^a Tibotec BVBA Johnson Johnson ^*  (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Campus de Maigremont   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CERULETIDE; CG 400549; FATTY ACID; ISONIAZID; LINEZOLID; PLATENSIMYCIN; TRICLOSAN; TYPE II FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL STRAIN; DOWN REGULATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG PROTEIN BINDING; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; FATTY ACIDS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRICLOSAN;

STAPHYLOCOCCUS AUREUS;

EID: 75149139456     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08667     Document Type: Note

References (15)

1. Brinster, S. etal. TypeII fatty acid synthesis isnot a suitable antibiotic target for Gram-positive pathogens. Nature 458, 83-86 (2009).
2. Weidenmaier, C. et al. DltABCD-and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 73, 8033-8038 (2005).
3. Peschel, A. et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 193, 1067-1076 (2001).
4. Koul, A., Herget, T., Klebl, B. & Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nature Rev. Microbiol. 2, 189-202 (2004).
5. Finlay, B. B. & Cossart, P. Exploitation of mammalian host cell functions by bacterial pathogens. Science 276, 718-725 (1997).
6. Ji, Y. et al. Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol. Lett. 231, 177-184 (2004).
7. Marrakchi, H., Zhang, Y. M. & Rock, C. O. Mechanistic diversity and regulation of Type II fatty acid synthesis. Biochem. Soc. Trans. 30, 1050-1055 (2002).
8. Altabe, S., Lopez, P. & de Mendoza, D. Isolation and characterization of unsaturated fatty acid auxotrophs of Streptococcus pneumoniae and Streptococcus mutans. J. Bacteriol. 189, 8139-8144 (2007).
9. Zhang, Y. M. & Rock, C. O. Membrane lipid homeostasis in bacteria. Nature Rev. Microbiol. 6, 222-233 (2008)
10. Omura, S. Cerulenin. Methods Enzymol. 72, 520-532 (1981).
11. Heath, R. J., White, S. W. & Rock, C. O. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 40, 467-497 (2001).
12. Wang, J. et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358-361 (2006).
13. Yum, J. H. et al. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob. Agents Chemother. 51, 2591-2593 (2007).
14. Payne, D. J. et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124 (2002).
15. Vilcheze, C. et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nature Med. 12, 1027-1029 (2006).